The renin–angiotensin system (RAS) plays a pivotal role in the initiation and progression of hepatocellular carcinoma (HCC). Through its regulation of angiogenesis, tissue fibrosis, and immune cell activity, RAS profoundly shapes the tumor microenvironment (TME), thereby promoting tumor growth and metastasis. Activation of RAS enhances tumor vascularization while concurrently suppressing anti-tumor immune responses, contributing to immune evasion. Preclinical studies have demonstrated that RAS inhibitors can counteract these pro-tumorigenic processes by remodeling the TME and enhancing immune cell infiltration. Our summary indicates that treatment with RAS inhibitors synergizes with immune checkpoint blockade, markedly strengthening anti-tumor immunity and improving therapeutic efficacy in experimental models. Although the clinical benefits of RAS inhibitors as monotherapy remain limited, their integration with immunotherapy, targeted agents, or anti-angiogenic therapies has revealed considerable synergistic potential. Future research should aim to elucidate the precise mechanisms by which RAS regulates immune modulation in HCC and to optimize combination regimens that enable more effective and personalized therapeutic strategies for patients.
BaloghJVictorDAshamEH, et al.Hepatocellular carcinoma: a review. JHC2016; 3: 41–53.
2.
ZampaglioneLFerrariJVietti VioliN, et al.The role of extrahepatic features on the development and management of hepatocellular carcinoma in steatotic liver disease. Discov Med2024; 36: 1127.
3.
Díaz-GonzálezÁFornerARodríguez De LopeC, et al.New challenges in clinical research on hepatocellular carcinoma. Rev Esp Enferm Dig2015; 108: 485–493.
4.
SunCMaSChenY, et al.Diagnostic value, prognostic value, and immune infiltration of LOX family members in liver cancer: bioinformatic analysis. Front Oncol2022; 12: 843880.
5.
QiFLiJQiZ, et al.Comprehensive metabolic profiling and genome-wide analysis reveal therapeutic modalities for hepatocellular carcinoma. Research2023; 6: 0036.
6.
LiuDLiuLZhaoX, et al.A comprehensive review on targeting diverse immune cells for anticancer therapy: beyond immune checkpoint inhibitors. Crit Rev Oncol Hematol2025; 210: 104702.
7.
YangJChenCWangS, et al.Comprehensive genomic analysis of early and late-onset hepatocellular carcinoma. Genes Dis2024; 11: 101031.
8.
TieYTangFWeiY, et al.Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol2022; 15: 61.
9.
SensiBAngelicoRTotiL, et al.Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation. CMP2024; 17: e18761429310703.
10.
GaoYYuJLiZ, et al.Glucose metabolism perturbations influence tumor microenvironments via LINC01139 pathway and facilitate immunotherapy in hepatocellular carcinoma. Genes Dis2025; 12: 101302.
11.
ZhangHChenJZhangQ, et al.Oncogenic viral antigens for engineered T cell immunotherapy: challenges and opportunities. Med Adv2023; 1: 306–317.
12.
ChaudharyAYadavPChaudharyP, et al.Immunomodulatory role of T cell immunoglobulin and mucin domain-3 in cancer. Discov Med2025; 37: 31.
13.
SparksMACrowleySDGurleySB, et al.Classical renin-angiotensin system in kidney physiology. In: TerjungR (ed.) Comprehensive physiology. Hoboken, NJ: Wiley, 2014, pp.1201–1228.
14.
KumarRThomasCMYongQC, et al.The intracrine renin–angiotensin system. Clin Sci2012; 123: 273–284.
15.
IndiniARijavecEGhidiniM, et al.Targeting KRAS in solid tumors: current challenges and future opportunities of novel KRAS inhibitors. Pharmaceutics2021; 13: 53.
16.
AlqudahABarakatMAlzaghariLF, et al.Mechanistic insights into isorhamnetin: Targeting MAPK and NF-κB pathways to mitigate LPS-induced inflammation. CMP2025; 17: e18761429385248.
17.
HoC-MLeeC-HLeeM-C, et al.Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer2018; 18: 01.
18.
BoumelhaJMolina-ArcasMDownwardJ. Facts and hopes on RAS inhibitors and cancer immunotherapy. Clin Cancer Res2023; 29: 5012–5020.
CareyRM. The intrarenal renin-angiotensin system in hypertension. Adv Chronic Kidney Dis2015; 22: 204–210.
21.
WangWBodigaSDasSK, et al.Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev2012; 17: 683–691.
22.
ChappellMCMarshallACAlzayadnehEM, et al.Update on the angiotensin converting enzyme 2-angiotensin (1–7)-mas receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol2014; 4: 201.
23.
GallagherPEArterALDengG, et al.Angiotensin-(1-7): a peptide hormone with anti-cancer activity. CMC2014; 21: 2417–2423.
24.
SansoèGAragnoMWongF. Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. Liver Int2020; 40: 18–31.
25.
YangLGaoZ-WWuX-N, et al.CD73 Blockade alleviated hepatic fibrosis via inhibiting hepatic stellate CellsProliferation and activation. CMP2023; 17: e220323214863.
26.
NishidaN. Role of oncogenic pathways on the cancer immunosuppressive microenvironment and its clinical implications in hepatocellular carcinoma. Cancers (Basel)2021; 13: 3666.
27.
TripathiKGargM. Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer. J Cell Commun Signal2018; 12: 513–527.
28.
WenH. Oxidative stress-mediated effects of angiotensin II in the cardiovascular system. WJH2012; 2: 34.
29.
FanHWangCLiuS, et al.Therapeutic potential of natural products in stress granules: underlying molecular mechanisms and future perspectives. Curr Pharm Anal2025; 21: 88–99.
30.
MaJFuSTanJ, et al.Mechanistic foundations of KRAS-driven tumor ecosystems: integrating crosstalk among immune, metabolic, microbial, and stromal microenvironment. Adv Sci2025; 12: e02714.
31.
DiwanRGaytanSLBhattHN, et al.Liver fibrosis pathologies and potentials of RNA based therapeutics modalities. Drug Deliv and Transl Res2024; 14: 2743–2770.
32.
AcconciaF. The network of Angiotensin receptors in breast cancer. Cells2020; 9: 1336.
33.
GudivadaIPAmajalaKC. Integrative bioinformatics analysis for targeting hub genes in hepatocellular carcinoma treatment. CG2025; 26: 48–80.
34.
KimJWAbudayyehOOYeernaH, et al.Decomposing oncogenic transcriptional signatures to generate maps of divergent cellular states. Cell Syst2017; 5: 105–118.e9.
35.
GomaseVSDhamaneSPKakadePG. Immunoproteomics: a review of techniques, applications, and advancements. PPL2024; 31: 827–849.
36.
HoshidaYToffaninSLachenmayerA, et al.Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis2010; 30: 035–051.
37.
AbbasGSilveiraMGLindorKD. Hepatic fibrosis and the Renin-angiotensin system. Am J Ther2011; 18: e202–e208.
38.
MacconiDRemuzziGBenigniA. Key fibrogenic mediators: old players. Renin–angiotensin system. Kidney Int Suppl (2011)2014; 4: 58–64.
39.
KharaishviliGSimkovaDBouchalovaK, et al.The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int2014; 14: 41.
40.
PallaschFBSchumacherU. Angiotensin inhibition, TGF-β and EMT in cancer. Cancers (Basel)2020; 12: 2785.
41.
BurnsWCThomasMC. Angiotensin II and its role in tubular epithelial to mesenchymal transition associated with chronic kidney disease. Cells Tissues Organs2011; 193: 74–84.
42.
ZhengKHaoFMedrano-GarciaS, et al.Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis. Cell Death Dis2023; 14: 14.
43.
ZhangH-FGaoXWangX, et al.The mechanisms of renin–angiotensin system in hepatocellular carcinoma: from the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures. Biomed Pharmacother2021; 141: 111868.
44.
KimJ-YLeeJ-Y. Targeting tumor adaption to chronic hypoxia: implications for drug resistance, and how it can be overcome. IJMS2017; 18: 1854.
45.
ChauhanVPStylianopoulosTBoucherY, et al.Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng2011; 2: 281–298.
46.
Bottsford-MillerJNColemanRLSoodAK. Resistance and Escape from antiangiogenesis therapy: clinical implications and future strategies. JCO2012; 30: 4026–4034.
47.
ChenCWangZDingY, et al.Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol2023; 14: 1133308.
48.
PanYYuYWangX, et al.Tumor-Associated macrophages in tumor immunity. Front Immunol2020; 11: 583084.
49.
CrowleySDRudemillerNP. Immunologic effects of the renin-angiotensin system. JASN2017; 28: 1350–1361.
50.
WardABKeetonABChenX, et al.Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. MedComm2020; 1: 121–128.
51.
MossentaMBusatoDDal BoM, et al.Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies. Cancers (Basel)2020; 12: 1668.
52.
DeLibertyJMRobbRGatesCE, et al. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain. Adv Cancer Res2022; 153: 267–304.
53.
BartolacciCAndreaniCEl-GammalY, et al.Lipid metabolism regulates oxidative stress and ferroptosis in RAS-driven cancers: a perspective on cancer progression and therapy. Front Mol Biosci2021; 8: 706650.
54.
FooCHJPervaizS. gRASping the redox lever to modulate cancer cell fate signaling. Redox Biol2019; 25: 101094.
55.
WangJLuYZhangR, et al.Modulating and imaging macrophage reprogramming for cancer immunotherapy. Phenomics2024; 4: 401–414.
56.
SobczukPSzczylikCPortaC, et al.Renin angiotensin system deregulation as renal cancer risk factor (Review). Oncol Lett2017; 14: 5059–5068.
57.
ParkYKangDSinnDH, et al.Effect of renin-angiotensin system inhibitor in incident cancer among chronic hepatitis B patients: an emulated target trial using a nationwide cohort. J Renin Angiotensin Aldosterone Syst2024; 25: 14703203241294037.
58.
KachaveRNBhandariDDPingalePL, et al.Impurity profiling and forced degradation studies of Angiotensin (AT1) blockers: a review. Curr Pharm Anal2025; 21: 128–144.
59.
ZhaoGWangTLuanY, et al.Research progress on the correlation between renin-angiotensin-aldosterone system (RAAS) and cardiovascular and cerebrovascular diseases. J Renin Angiotensin Aldosterone Syst2025; 26: 14703203251351194.
60.
CrouchetELiSSojoodiM, et al.Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight2022; 7: e159254.
61.
SabitHArnethBAbdel-GhanyS, et al.Beyond cancer cells: how the tumor microenvironment drives cancer progression. Cells2024; 13: 1666.
62.
CsermelyPKorcsmárosTNussinovR. Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy. Semin Cell Dev Biol2016; 58: 55–59.
63.
LiGCheXWangS, et al.The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy. Ann Med2025; 57: 2447403.
64.
AzziSHebdaJKGavardJ. Vascular permeability and drug delivery in cancers. Front Oncol2013; 3: 211.
65.
FaivreSRimassaLFinnRS. Molecular therapies for HCC: looking outside the box. J Hepatol2020; 72: 342–352.
66.
PinterMKwantenWJJainRK. Renin–angiotensin system inhibitors to mitigate cancer treatment–related adverse events. Clin Cancer Res2018; 24: 3803–3812.
67.
Molina-ArcasMDownwardJ. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell2024; 42: 338–357.
68.
PatelKLammRAltshulerP, et al.Hepatocellular carcinoma—the influence of immunoanatomy and the role of immunotherapy. IJMS2020; 21: 6757.
69.
FanPZhangNCandiE, et al.Alleviating hypoxia to improve cancer immunotherapy. Oncogene2023; 42: 3591–3604.
70.
PinterMJainRK. Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy. Sci Transl Med2017; 9: eaan5616.
71.
KohliASSanyalSKaushalRS, et al.An insight into immunological therapeutic approach against cancer: potential anti-cancer vaccines. CG2025; 26: 175–190.
72.
XuZZhouHLiT, et al.Application of biomimetic nanovaccines in cancer immunotherapy: a useful strategy to help combat immunotherapy resistance. Drug Resist Updates2024; 75: 101098.
73.
CabibboGCelsaCRimassaL, et al.Navigating the landscape of liver cancer management: study designs in clinical trials and clinical practice. J Hepatol2024; 80: 957–966.
74.
MiaoGGuoJZhangW, et al.Remodeling intestinal Microbiota alleviates severe combined hyperlipidemia-induced nonalcoholic steatohepatitis and atherosclerosis in LDLR−/− hamsters. Research2024; 7: 0363.
75.
LlovetJMBruixJ. Molecular targeted therapies in hepatocellular carcinoma†. Hepatology2008; 48: 1312–1327.
76.
KakehashiASuzukiSWanibuchiH. Recent insights into the biomarkers, molecular targets and mechanisms of non-alcoholic steatohepatitis-driven hepatocarcinogenesis. Cancers (Basel)2023; 15: 4566.
77.
PanYChenHYuJ. Biomarkers in hepatocellular carcinoma: current Status and future perspectives. Biomedicines2020; 8: 76.
78.
NaikALeaskA. Tumor-associated fibrosis impairs the response to immunotherapy. Matrix Biol2023; 119: 125–140.
79.
KumarVRahmanMGahtoriP, et al.Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Delivery2021; 18: 673–694.
80.
KlaverYKunertASleijferS, et al.Adoptive T-cell therapy: a need for standard immune monitoring. Immunotherapy2015; 7: 513–533.
81.
QinHJiZZhaoQ, et al.Contrast-enhanced ultrasound features of primary hepatic lymphoepithelioma-like carcinoma: comparison with hepatocellular carcinoma. BIOI2024; 5: 2023-0019.
82.
DuJAnZ-JHuangZ-F, et al.Novel insights from spatial transcriptome analysis in solid tumors. Int J Biol Sci2023; 19: 4778–4792.
83.
HeoYJHwaCLeeG-H, et al.Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. Mol Cells2021; 44: 433–443.
84.
FeiXDuXWangJ, et al.Precise diagnosis and risk stratification of prostate cancer by comprehensive serum metabolic fingerprints: a prediction model study. Int J Surg2024; 110: 1450–1462.
85.
ZhuoJLLiXC. New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides2011; 32: 1551–1565.
86.
LiuYXieBChenQ. RAS Signaling and immune cells: a sinister crosstalk in the tumor microenvironment. J Transl Med2023; 21: 95.
87.
SimõesESilvaASilveiraK, et al.ACE2, Angiotensin-(1-7) and M as receptor axis in inflammation and fibrosis. Br J Pharmacol2013; 169: 477–492.
88.
CastellanoEDownwardJ. RAS Interaction with PI3K: more than just another effector pathway. Genes Cancer2011; 2: 261–274.
89.
ChoiYJungK. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med2023; 55: 2308–2319.
90.
LiZLuoBChenY, et al.Nanomaterial-based encapsulation of biochemicals for targeted sepsis therapy. Materials Today Bio2025; 33: 102054.
91.
LadePDSinglaN. Formulation and development of Tara Gum-mediated tablets for delivery of anticancer drugs. BIOI2024; 5: 2024-0040.
92.
GrewalAKSalarRK. Chitosan nanoparticle delivery systems: an effective approach to enhancing efficacy and safety of anticancer drugs. Nano TransMed2024; 3: 100040.
93.
ZhangWWanZQuD, et al.Profibrogenic macrophage-targeted delivery of mitochondrial protector via exosome formula for alleviating pulmonary fibrosis. Bioact Mater2024; 32: 488–501.
94.
LiF-QChenW-BLuoZ-W, et al.Bone marrow mesenchymal stem cell-derived exosomal microRNAs target PI3K/akt signaling pathway to promote the activation of fibroblasts. World J Stem Cells2023; 15: 248–267.
95.
BöttgerRPauliGChaoP-H, et al.Lipid-based nanoparticle technologies for liver targeting. Adv Drug Delivery Rev2020; 154–155: 79–101.
96.
AgrawalSKJainSSAgrawalM. Precision Medicine: Transforming Cancer Research through Targeted Therapies. CG2025; 26: e13892029357275.
97.
GaoBDuanW. The current status and future directions of artificial intelligence in the prediction, diagnosis, and treatment of liver diseases. DIGITAL HEALTH2025; 11: 20552076251325418.
98.
RajGMDananjayanSGudivadaKK. Applications of artificial intelligence and machine learning in clinical medicine: what lies ahead ?Med Adv2024; 2: 202–204.
99.
WangHLiXYouX, et al.Harnessing the power of artificial intelligence for human living organoid research. Bioact Mater2024; 42: 140–164.
100.
LiuXZhangSShaoL, et al.Improving prediction of treatment response and prognosis in colorectal cancer with AI-based medical image analysis. TIME2024; 2: 100069.
101.
ChandaranaCVMithaniNTSinghDV, et al.Vibrational spectrophotometry: a comprehensive review on the diagnosis of gastric and liver cancer. CPA2024; 20: 453–465.
102.
De La Orden Kett MoraisSRFelderFNWalshSLF. From pixels to prognosis: unlocking the potential of deep learning in fibrotic lung disease imaging analysis. Br J Radiol2024; 97: 1517–1525.
103.
WuJLiuWQiuX, et al.A noninvasive approach to evaluate tumor immune microenvironment and predict outcomes in hepatocellular carcinoma. Phenomics2023; 3: 549–564.
104.
GarciaVMCassierPADe BonoJ. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress. Cancer Discov2011; 1: 207–212.
105.
GaluppoRRamaiahDPonteOM, et al.Molecular therapies in hepatocellular carcinoma: what can we target?Dig Dis Sci2014; 59: 1688–1697.
106.
SongRLiuFPingY, et al.Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction. Biomark Res2023; 11: 57.
107.
ChauleauJ-YTrassinM. Sensing multiferroic states non-invasively using optical second harmonic generation. Microstructures2024; 4: 2024005.
108.
NassSJCogleCRBrinkJA, et al.Improving cancer diagnosis and care: patient access to oncologic imaging expertise. JCO2019; 37: 1690–1694.
109.
FinnRS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?Clin Cancer Res2010; 16: 390–397.
110.
Fernandez-MoureJS. Lost in translation: the gap in scientific advancements and clinical application. Front Bioeng Biotechnol2016; 4: 43.
111.
PuljakLVariSG. Significance of research networking for enhancing collaboration and research productivity. Croat Med J2014; 55: 181–183.
112.
SohalDDoudementJGeorgeB, et al.Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC). JCO2019; 37: 6557–6557.
113.
SundaresanSRajapriyaP. Translational Perspective in Hepatocellular Carcinoma.. In: SundaresanSGuY-H (eds) Translational Research in Cancer. London: IntechOpen, 2021.
